Safety and preliminary efficacy of allogeneic bone marrow-derived multipotent mesenchymal stromal cells for systemic sclerosis: a single-centre, open-label, dose-escalation, proof-of-concept, phase 1/2 study

Dominique Farge, Karin Tarte, Matthieu Resche‐Rigon et al.|The Lancet Rheumatology|2022

Cited by 38